Phaseline

Targets › TERC

TERC: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Mar 2027.

Open in Phaseline: the race on TERC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Åslaug HellandUV1 vaccine
Therapeutic cancer vaccine targeting telomerase (hTERT) to activate hTERT-specific T cells
TERCPhase 2CancerMar 2027
Centre Hospitalier Universitaire de BesanconUCPVax
CD4 Th1-inducing cancer vaccine targeting telomerase
TERCPhase 2Hepatocellular CarcinomaMar 2028

Conditions

Cancer (1) Hepatocellular Carcinoma (1)

Modalities

mixed (2)

Companies

Åslaug Helland (1) Centre Hospitalier Universitaire de Besancon (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.